

## PROGRAM - P. 1

PATIENT ACCESS TO HEALTH IN CEE - ENABLING VALUE-DRIVEN HEALTHCARE DECISIONS

**THURSDAY - 20.04** 

**FRIDAY - 21.04** 

**SATURDAY - 22.04** 

#### **SESSION 1**

10:00 - 11:30

Pre-Congress Workshop in Collaboration with Prof. Zoltan Kalo, Syreon Research Institute

Health technology assessment in Europe: from birth to puberty

09:00 - 10:45

Pharmaceutical Pricing, International Referencing and Public Funding - any light at the end of a tunnel?

Tiered based pricing, combination pricing, external price referencing and its impact to patient access, horizone scanning and its utilization for appropriate and strategic allocation of public funding.

09:00 - 10:45

Affordability Challenges and Emerging Financing Models for ATMPs in CEE region

National stakeholders need to create a balance between ensuring patient access to breakthrough therapies and maintaining the financial sustainability of the healthcare system. What are the new pathways and funding strategies for these innovative high-cost therapies and how could they be implemented in CEE region?

**COFFEE BREAK (Shakespeare Hall, Grand Hotel Millenium)** 

11:30-12:00 10:45-11:15 10:45-11:15

#### **SESSION 2**

12:00 - 13:30

Pre-Congress Workshop in collaboration with Prof. Zoltan Kalo, Syreon Research Institute

Health technology assessment in Europe: from birth to puberty

11:15 - 13:00

Value Based Health Care Decision Making in CEE a myth or a dream?

The goal of value-based care transformation is to enable the health care system to create more value for patients. How to maximize health outcomes across CEE region, despite limited budgets, reduced personnel, and inadequate time.

11:15 - 12:55

Health Economic Aspects of Emerging Treatment Modalities

Methodological considerations and best practice sharing

13:00 – 13:20 CONGRESS CLOSING CEREMONY

#### LUNCH

(Shakespeare Hall, Grand Hotel Millenium)

**13:30-14:00** (Workshop participants only)

#### LUNCH

(Shakespeare Hall, Grand Hotel Millenium)

13:00-14:00

13:30 – 15:30 Collaborative Associations' Meeting (by invitation only)

- Feedback from this year congress
- Venue and topics for next year congress
- Opportunities for collaboration between congresses

15:30 - 16:30 DEPARTURES



# PROGRAM - P. 2

PATIENT ACCESS TO HEALTH IN CEE - ENABLING VALUE-DRIVEN HEALTHCARE DECISIONS

**THURSDAY - 20.04** 

**FRIDAY - 21.04** 

#### **SESSION 3**

14:00 - 15:50 CONGRESS OPENING CEREMONY

#### **KEY-NOTE SPEECHES**

The Evolution of Access to Health in Bulgaria over the last decade

Government Perspective on Access to Health in Bulgaria

Patient Perspective on Access to Health in Bulgaria

14:00 - 16:40 ROUNDTABLE

#### **EU General Pharmaceutical Legislation**

As part of the EU pharmaceuticals strategy, the Commission plans to evaluate and revise the EU's general legislation on medicines to ensure a future-proof and crisis-resistant regulatory environment.

### ROUNDTABLE INTRODUCTION SPEECHES (setting the scene):

EU General Pharmaceutical Legislation -Patient expectations, Implementation (un)readiness and Industry perspective

#### **Roundtable participants:**

National (government and academia) stakeholders from CEE region, Patient Associations' representatives, Industry representatives

**COFFEE BREAK (Shakespeare Hall, Grand Hotel Millenium)** 

15:50-16:15 16:40-17:10

#### **SESSION 4**

16:15 - 18:30 ROUNDTABLE

EU HTA Regulation - Implementation Readiness in CEE region

Implementation challenges and expected benefits of the EU HTA regulation for CEE countries

ROUNDTABLE INTRODUCTION SPEECHES (setting the scene):

EU HTA Regulation - Patient expectations, Implementation (un)readiness and Industry perspective

**Roundtable participants:** 

National stakeholders from CEE countries, EU HTA experts, Industry representatives 17:10 - 18:30

Importance of RWE in Value Based Decision Making

How to drive the sustainable development and adoption of tools, methods and best practices in the generation and use of real world evidence for better health care decision-making in CEE region; Transferability of RWD.

**SOCIAL NETWORKING (Shakespeare Hall, Grand Hotel Millenium)** 





https://www.farmaforum.si/en





LET'S MAKE ACCESS
TO MEDICINES



# FASTER

Access to treatments across EU takes 511 days on average, ranging from 133 days in Germany to 899 days in Romania

We commit to filing Pricing & Reimbursement applications post EU authorization in all EU-27 member states as quickly as possible, and no later than 2 years.

LET'S MAKE
INTRODUCING NEW
MEDICINES MORE

¥ ₹

### **SUSTAINABLE**

Cutting-edge treatments bring new challenges for health systems.

With novel payment models we can **spread the cost of these treatments** over the time that patients
benefit from them

# **FAIRER**

Each country's ability to pay for innovative medicines is different

We need a **new framework that varies prices** between member states depending on their economic

LET'S MAKE
THE BARRIERS



# CLEARER

There are 10 factors that delay patient access to new treatments.

We've developed a portal where companies record the launch progress of each medicine in each Member State and the reasons behind delays to help us find solutions together.








#WeWontRest

### INFORMATION CAMPAIGN IN SUPPORT OF ORGAN DONATION



Astellas Pharma EOOD | 90 Tsarigradsko shose Blvd. | Capital Fort Office Building | floor.11 | 1784, Sofia | Bulgaria | Tel: +359 2 862 53 72

MAT-BG-NON-2023-00021 | Date of preparation: April 2023

# Driving change for generations



Since the beginning of our company, we have been working to help people with chronic diseases live full and healthy lives. While people today are living longer than ever before, rising rates of obesity and diabetes threaten the health and prosperity of future generations.

We are going beyond medicine to strengthen disease prevention and early intervention, driving change for the health of generations to come - with the ultimate aspiration of a world free from the burden of chronic disease.

Discover more at: novonordisk.com





### **GOLD SPONSOR:**



### SILVER SPONSORS:







**BRONZE SPONSOR:** 

SUPPORTED BY GRANT:



